SLC2A1 and hepatocellular carcinoma: The results of molecular dockings showed that the selected drugs had good binding properties with the two proteins, which suggested that DLAT and SLC2A1 may serve as potential therapeutic targets and can act as biomarkers, aiding in drug development and HCC classification.